Containment Is a Governance Decision: Tissue Dissemination Risk in Laparoscopic Morcellation

‐

By Daniela Schardinger

Laparoscopic morcellation used during hysterectomy and myomectomy remains an important component of minimally invasive gynecologic surgery. However, tissue fragmentation without effective containment may disseminate malignant or viable tissue within the peritoneal cavity, with potential implications for patient safety, oncologic outcomes, benign disease burden, and institutional liability.

In an era of heightened scrutiny around tissue dissemination and cancer risk, containment is not merely a surgical technique, it is a governance decision.

Clinical risk: Beyond a rare event

FDA analyses have estimated that unsuspected uterine sarcoma may occur in approximately one in 225 to one in 580 women undergoing hysterectomy or myomectomy for presumed benign fibroids, with earlier communications citing an estimate near one in 350. (FDA, 2014; FDA, 2017).

When morcellation is performed without effective containment in such cases, malignant cells may be disseminated throughout the peritoneal cavity. This may result in cancer upstaging, altered treatment pathways, and reduced long-term survival probability.

At the same time, tissue dissemination is not limited to malignancy. Fragmentation of benign tissue may also result in implantation within the abdominal cavity, including parasitic fibroids or endometrial tissue, potentially increasing disease burden and contributing to recurrence or additional surgical intervention.

Practice variability and real-world risk

Recent survey data suggest that containment practices vary across institutions, including differences in containment system selection, continued use of devices not specifically cleared for morcellation, and inconsistent documentation of containment approach (Connell et al., Gynecology & Reproductive Health, 2025).

Importantly, respondents have reported instances of containment bag rupture or compromise during morcellation procedures. While reported rates vary, these findings underscore that containment failure is not purely theoretical.

Within a single health system, such variability may translate into differences in oncologic risk, benign tissue dissemination risk, and documentation defensibility.

A shifting regulatory and legal landscape

Off-label use of medical devices remains legally permissible within physician discretion. However, the availability of FDA-cleared containment systems specifically engineered for morcellation introduces a new layer of institutional responsibility.

In litigation, scrutiny often extends beyond individual clinical decisions to include institutional oversight. Common areas of inquiry include:

  • Whether containment was used
  • Whether the device was FDA-cleared for morcellation
  • Whether rupture risk was considered
  • Whether cancer dissemination risk was discussed with the patient
  • Whether the containment device was documented in the operative report

When documentation is limited to generic terms such as “specimen bag,” retrospective defensibility may be challenged.

Informed consent and patient expectations

Patients are increasingly informed and may revisit surgical decisions years later. Questions such as whether containment was used, whether the system was FDA-cleared, and whether dissemination risk was discussed are becoming more common.

Many institutions do not maintain device-specific consent language, raising governance questions around whether current consent processes adequately reflect the evolving risk landscape.

From surgical preference to institutional governance

Variability in containment approach is often driven by individual surgeon preference. However, as regulatory guidance evolves and FDA-cleared options become available, containment decisions may increasingly fall within the scope of institutional governance.

For hospital leadership, this raises key questions:

  • Are containment systems formally reviewed through the Value Analysis Committee (VAC)?
  • Are containment approaches standardized across surgeons?
  • Are documentation and consent practices aligned with current risk considerations?

In this context, containment is no longer solely a technical decision in the operating room, it is a policy and oversight decision at the institutional level.

Practical steps for risk and quality leaders

Hospitals evaluating their approach to morcellation containment may consider:

  • Conducting formal VAC review of containment systems
  • Documenting evaluation of FDA-cleared alternatives
  • Standardizing operative documentation of containment device type
  • Reviewing consent language related to tissue dissemination risk
  • Engaging risk management and legal counsel in policy review

Structured checklists can support consistency in evaluation, documentation, and governance processes.

Conclusion

Laparoscopic morcellation continues to play an important role in gynecologic surgery. However, the risks associated with tissue dissemination—whether malignant or benign—are increasingly intersecting with questions of institutional oversight, documentation, and defensibility.

As expectations evolve, hospitals may need to reassess whether current containment practices align not only with surgical workflow, but also with patient safety standards and governance responsibilities.

Containment, in this context, is not simply a technical consideration. It is a reflection of institutional risk management.

Daniela Schardinger is an industry expert in women’s health innovation and member of the Innovation Equity Steering Committee (Gates Foundation and NIH) and the World Economic Forum Global Women’s Health Alliance.